Last updated on November 2016

Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma


Brief description of study

The purpose of Part 1 of this study is to evaluate the safety and tolerability of dalantercept in combination with axitinib in patients with advanced renal cell carcinoma (RCC) to determine the recommended dose level of dalantercept in combination with axitinib for Part 2. The purpose of Part 2 of this study is to determine whether treatment with dalantercept in combination with axitinib prolongs progression free survival (PFS) compared to axitinib alone in patients with advanced renal cell carcinoma (RCC).

Clinical Study Identifier: NCT01727336

Contact Investigators or Research Sites near you

Start Over

Clinical Trials Manager

North Shore LIJ Center for Advance Medicine
Lake Success, NY United States
  Connect »